The safety record is thinner than it looks
Peptides are often described as having a favourable safety profile compared with conventional drugs, on the reasoning that they work through pathways the body already uses. The mechanism argument is fair as far as it goes. The conclusion drawn from it usually is not.
Approved medicines look riskier partly because their harms have been systematically hunted for, in trials designed to find them, with adverse events recorded and published. For most research peptides nobody is running that search. There is no registry, no mandatory reporting, and no long-term follow-up. What exists is short studies, case reports, and clinical anecdote.
A quiet safety record can mean a compound is well tolerated, or it can mean no one is collecting the data. For most of this category it is the second, and the honest position is that long-term safety is unknown rather than established. That is not a reason to panic. It is a reason not to treat "no reported problems" as "no problems".
Two things genuinely do shape individual risk, and both are controllable:
- Dose. Nearly all of these effects scale with it. Starting low and moving slowly is the single highest-value safety behaviour available to you.
- Source. With no regulator checking the vial, purity and sterility are entirely a function of who made it. See the sourcing checklist.
What usually happens
These are common, generally mild, and mostly settle as the body adjusts. They are worth expecting so you do not mistake them for something going wrong.
| Effect | Most associated with | Typical course |
|---|---|---|
| Injection site reactions redness, swelling, itching, soreness | Anything injected | Hours to a couple of days. Rotate sites |
| Nausea, bloating, altered bowel habit | GLP-1 agonists especially | Often eases over several weeks; worse after dose increases |
| Flushing, warmth, transient blood pressure shifts | GH secretagogues and vasoactive compounds | Minutes to hours after a dose |
| Appetite and taste changes | Metabolic compounds | Often the intended effect rather than a side effect |
| Sleep disruption or energy swings | GH secretagogues | Usually the first fortnight, then settles |
| Water retention, tingling, joint ache | GH secretagogues | Dose-related. Often resolves on reducing |
What occasionally happens
Less common, and the reason the sections after this one exist. None of these are reasons to assume disaster; all of them are reasons to know the signs.
| Risk | Who it matters most for | How well established |
|---|---|---|
| Allergic and anaphylactic reactions | Anyone, unpredictably. Rare but genuine | Well established for injectables generally |
| Hypoglycaemia | Anyone on insulin or sulfonylureas; diabetics | Well established, and the most likely serious event in this list |
| Injection-site infection or abscess | Anyone with imperfect sterile technique or an unsterile product | Well established, and largely preventable |
| Blood pressure and heart rhythm changes | Existing cardiovascular disease | Plausible; poorly quantified outside approved drugs |
| Suppression of natural production | Long or high-dose secretagogue use | Mechanistically expected; long-term extent unknown |
| Promotion of an existing tumour | Anyone with a current or recent cancer | Theoretical, not demonstrated — but the theory is coherent |
The tumour question deserves precision, because it is often stated badly in both directions. There is no evidence that growth hormone secretagogues cause cancer. The concern is narrower: GH and IGF-1 are growth signals, and raising a growth signal in someone who already has a malignancy is a theoretical way to help it along. It has not been shown to happen. It is also not the kind of risk you take speculatively, which is why an active cancer diagnosis rules these out until an oncologist says otherwise.
Who should not start
| Situation | Position |
|---|---|
| Active or recent cancer | Do not use GH secretagogues. Oncologist first, no exceptions |
| Pregnant, breastfeeding, or trying to conceive | Do not use. There is no safety data to reason from |
| Under 18 | Do not use. Growth and development effects are unstudied and unpredictable |
| Unstable cardiovascular disease recent infarct, unstable angina, severe heart failure | Do not use without cardiology input |
| Advanced diabetic complications retinopathy, nephropathy, frequent hypos | Specialist management only |
| Psychiatric conditions on medication | Caution, particularly with anything neuroactive. Prescriber first |
| Older adults | Not excluded, but expect more sensitivity, more interactions, slower titration |
Interactions that actually matter
This is the part people most often skip and most often regret. Take the list to whoever prescribes your medication rather than deciding it yourself.
| If you take | The problem | What it means |
|---|---|---|
| Insulin or sulfonylureas | Additive glucose lowering | Real hypoglycaemia risk. Doses usually need reducing, with medical supervision |
| Any oral medication with GLP-1 agonists |
Slowed gastric emptying changes absorption | Matters most for narrow-margin drugs and oral contraceptives |
| Blood pressure medication | Additive or unpredictable effects | Monitor at home, especially in the first weeks |
| Anticoagulants | Bleeding and bruising, including at injection sites | Discuss before starting anything injected |
| Antidepressants and mood stabilisers | Overlapping neurotransmitter effects | Unpredictable. Applies mainly to Semax, Selank and similar |
| Thyroid or hormone therapy | Interacting endocrine axes | Recheck levels after starting; do not assume stability |
Not infecting yourself
Infection is the most preventable serious complication here, and it comes from technique and product rather than from the compound.
- Wash hands, clean the surface, alcohol-swab the vial top and the skin, and let it dry before the needle goes in. Wet alcohol stings and does not work.
- One needle, one use. Reusing blunts the tip, hurts more, and carries contamination in.
- Rotate sites on a fixed pattern. Repeated injection in one spot causes lumps, scarring, and erratic absorption.
- Respect the storage rules. Most need refrigeration and most degrade once mixed. Bacteriostatic water is not sterile water, and a few compounds are actively harmed by it — see the exceptions before mixing.
- Sharps go in a proper container, never in household waste.
- Never share needles or vials. Multi-dose vials are single-person items.
Spreading redness, increasing pain after the first day, heat, hardness, or fever is not a normal injection reaction. That is a possible infection and needs to be seen the same day.
What to check, and when
- Before you start. A baseline is the only thing that makes later numbers interpretable. Depending on what you are running that usually means fasting glucose and HbA1c, a lipid panel, kidney and liver function, blood pressure, and relevant hormone levels.
- In the first month. Blood pressure at home, weight, and a written note of side effects as they happen rather than reconstructed later.
- Every few months. Repeat the relevant bloods. For anything affecting glucose, glucose markers. For secretagogues, IGF-1 — the one number that shows whether the intervention is doing what it is supposed to.
- Ongoing. Ask the risk-benefit question again periodically. Circumstances change, and "I have always taken it" is not a reason.
Stop and get help
Difficulty breathing, swelling of the face, lips, tongue or throat, widespread rash or hives, sudden faintness with a racing pulse. This is anaphylaxis. It can progress in minutes. Call an ambulance — do not drive yourself, and do not wait to see whether it settles.
Chest pain, severe breathlessness, fainting, or an irregular pulse that does not settle. Treat as cardiac until a professional says otherwise.
Hypoglycaemia — shaking, sweating, confusion, blurred vision, sudden intense hunger — needs fast-acting sugar immediately, then a longer-acting carbohydrate once symptoms lift, then medical advice about the dose that caused it. If the person cannot swallow safely or loses consciousness, call an ambulance and do not put anything in their mouth.
Beyond those: stop and seek advice for severe or worsening vomiting, persistent abdominal pain radiating to the back, vision changes, or any effect that is getting worse rather than better after a few days. Stopping costs you a few weeks of progress. Continuing through a warning sign can cost considerably more.
Tell your doctor
The most common avoidable harm in this space is not a side effect. It is a clinician treating someone while missing a compound they are taking, because the patient did not mention it.
Concealment is understandable — people expect judgement, and sometimes get it. It is still the wrong trade. A doctor who knows what you are on can interpret your bloods, spot an interaction, and treat you properly in an emergency. One who does not is working blind. If you are treated urgently, that information changes what is safe to give you.
Find someone experienced with hormone and peptide therapy if you can; not every clinician is. But telling an unenthusiastic doctor is still far better than telling none.
Before you act on any of this
This is a general summary for education, not guidance for your situation, and it is not a substitute for assessment by someone who knows your history. It contains no doses deliberately. Nothing here should be used to decide whether to start, continue, or stop anything — least of all a prescribed medicine. If you think you are having a serious reaction, contact emergency services rather than looking for an answer on a website.
Sources
Mechanism, category and regulatory statements follow the reference list in the foundations primer, in particular the FDA's Category 2 compounding list and the WADA Prohibited List. Emergency thresholds above follow standard first-aid guidance for anaphylaxis and hypoglycaemia; they are deliberately conservative. The likelihood language throughout reflects that systematic adverse-event data does not exist for most of these compounds — which is itself the finding in the first section.